齐拉西酮与利培酮治疗难治性精神分裂症对照研究

A control study of ziprasidone vs. risperidone in refractory schizophrenia

目的评价齐拉西酮与利培酮治疗难治性精神分裂症的临床疗效及安全性。方法将60例难治性精神分裂症患者随机分为两组各30例，研究组口服齐拉西酮治疗，对照组口服利培酮治疗，观察12w。于治疗前及治疗第4w、8w、12w末采用阳性与阴性症状评定量表评定临床疗效、副反应量表评定不良反应。结果治疗第4w末起两组阳性与阴性症状评定量表总分及各因子分均较治疗前有显著下降（P〈0．01），并随着治疗的延续呈持续性下降，但治疗12w末研究组阴性症状因子分较对照组下降更显著（P〈0．05）。研究组不良反应发生率为53．3％，对照组为66．7％；研究组治疗8w、12w末副反应量表评分显著低于对照组（P〈0．05）。结论齐拉西酮与利培酮治疗难治性精神分裂症效果均较好，但齐拉西酮适用于耐受差的患者。

Objective To evaluate the clinical efficacy and safety of ziprasidone vs. risperidone in refractory schizophrenia. Methods Sixty refractory schizophrenics were randomly assigned to two groups of 30 patients each, research group took orally ziprasidone and control group did risperidone for 12 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale（PANSS） and adverse reactions with the Treatment Emergent Symptom Scale（TESS） before treatment and at the ends of the 4th, 8th and 12th week treatment. Results Since the end of the 4th week, total and all factors＇ scores of the PANSS of both groups lowered more significantly compared with pretreatment and did continously along with treatment lasting; at the end the 12th week, those did more significantly in the research than in the control group（P〈0.05）. Incidences of adverse reactions were 53.3% in the research and 66.7% in the control respectively; scores of the TESS were significantly lower in the research than in the control at the ends of the 8th and 12th week（P〈0.05）. Conclusion Both ziprasidone and risperidone are available for refractory schizophrenia, but the former is available for the patients who have poor tolerance.